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Myocardial ischemia/reperfusion injuryAutophagy is an intracellular process responsible for damaged or unnecessary protein and organelle degradation.
In the heart, autophagy occurs at basal level and dysregulated autophagy is associatedwith a variety of cardiovas-
cular diseases. Autophagy is enhanced in ischemia as well as in the reperfusion phase during cardiac ischemia re-
perfusion (I/R) injury. More importantly, recent studies revealed that autophagy exerted both beneﬁcial and
detrimental effects in pathology of cardiac ischemia reperfusion. This paper is to review the functional signiﬁ-
cance of autophagy in cardiac ischemia reperfusion injury and discuss underlying signaling pathways. This article
is part of a Special Issue entitled: Autophagy and protein quality control in cardiometabolic diseases.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Autophagy is a cellular process associated with damaged or unnec-
essary protein and organelle degradation [1]. Previous evidences identi-
ﬁed autophagy as a protective intracellular process functioning as
protein quality controller and cellular homeostasis keeper. However, a
new type of cell death is proposed, namely “autophagic cell death” oc-
curring with autophagy, indicating the complexity of autophagy func-
tions [2,3]. In the heart, autophagy occurs at basal level under normal
conditions, contributing to cellular homeostasis through cleaning
long-lived or excessive proteins and aged organelles. Deletion of au-
tophagy can result in adverse effects in myocardium [4]. In addition, al-
tered autophagywas observed inmany other cardiovascular diseases in
response to pathological stimuli, including ischemic heart disease, car-
diac hypertrophy and heart failure [5].
There are basically three types of autophagy, namely,
macroautophagy,microautophagy and chaperone-mediated autophagy
(CMA). These three types differed in ways by which unnecessary
components are delivered into lysosomes for ﬁnal degradation [7].
Macroautophagy, with typical formation of autophagosome, is the
most characterized form of autophagy and is better illustrated in
mammalian cells. Macroautophagy is responsible for the degradation
of both cytoplasmic proteins and intracellular organelles, including en-
doplasmic reticulum (ER) and mitochondria. Notably, mitochondrialy and protein quality control in
, Chinese PLA General Hospital,autophagy is also termed as “mitophagy”, a process of selective clearance
of damaged mitochondria. Mitophagy is now considered as a protective
mechanism during cardiac I/R injury, and we will discuss about it in the
later part of this review. Apart from the abovementioned three basic
types of autophagy, Yuuki Fujiwara et al. reported two novel types of
autophagy, termed as “RNautophagy” and “DNautophagy” [8,9]. In these
two newly proposed autophagic pathways, RNA or DNA is directly
taken in anddegraded in lysosomes in anATP-dependentmanner,mainly
mediated by the lysosomal membrane protein of LAMP2C. However, the
physiological function of RNautophagy or DNautophagy remains unclear.
Acute myocardial infarction (AMI) is one of the major contributors
of morbidity and mortality in patients with coronary heart diseases
(CHD) worldwide [6]. Under the condition of cardiac ischemia reperfu-
sion injury (I/R injury), the process of autophagy is activated in response
to energy crisis and oxidative stress. However, current researches
demonstrate that autophagy can be a double-edged sword in the
pathological process of I/R injury. In this review, we aimed to dis-
cuss the complex functional contribution of autophagy in cardiac
I/R injury and identify potential signaling molecules for future clinical
development.
2. Molecular signal alternation of autophagy during myocardial
infarction and ischemia/reperfusion injury
The heart is comprised of long-lived cardiomyocytes with little
regenerative capacity. In myocardium, the self-digestive process of au-
tophagy could occur under normal conditions at a low level, contribut-
ing to cellular homeostasis through cleaning long-lived or excessive
proteins and aged organelles. Basal level of autophagy is fundamental
for cardiac structure and function as for its essential role of protein
and organelle quality control. Loss of genes that are essential for
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Atg5 are essentialmediatormolecules for autophagy, deﬁciency of these
genes leads to impaired autophagy, subsequent accumulation of abnor-
mal substrates and cardiac dysfunction. Clinical reports observed that
mutations of LAMP2, a principle lysosomal membrane protein, were
the cause of Danon disease, a condition of severe and progressivemyop-
athy [4]. In addition, K. Nishida et al. reported that Atg5 deﬁcient mice
hearts exhibited ventricular dilatation and dysfunction, accompanied
by accumulation of damaged proteins and organelles [10].
Altered autophagy is involved in a great number of cardiovascular
diseases such as dilated cardiomyopathy, heart failure, anticancer
drug-induced cardiomyopathy or ischemic heart disease, autophagy is
increased [5]. Decreased autophagic ﬂux activity is observed in glycogen
storage disease related cardiomyopathy, for instance, Danon disease is
characterized by abnormal accumulation of autophagosome due to de-
fective autophagosome–lysosome fusion. Autophagy is associated with
multiple cardiovascular diseases, either as a detrimental contributor to
the pathogenesis or as an adaptive response. However, it remains un-
knownwhether the autophagic alteration in these cardiovascular disor-
ders is adaptive or maladaptive. More preclinical studies and clinical
analysis should be performed to address this.2.1. Low ATP level induced AMPK activation upregulated autophagic
pathways during cardiac ischemia phase
Cardiac ischemia is characterized by initial restriction of blood sup-
ply and lowATP generation, leading to imbalance between blood supply
and energy demand, resulting in cardiomyocyte dysfunction and myo-
cardial damage. Adenosine monophosphate-activated protein kinase
(AMPK) is a sensitive sensor of cellular energy activated by the de-
creased level of ATP and high ratio of AMP/ATP under the condition of
nutrient deprivation. During the initial phase of ischemia, AMPK was
activated by low ATP level in cardiomyocytes. After activation, AMPK
regulates the induction of autophagy via direct or indirect ULK1modiﬁ-
cations. Previous studies reported that AMPK activated autophagy
through AMPK-mTORC1 signaling: AMPK inhibits mTORC1 through
phosphorylation of TSC2 and Raptor site, followed by the indirect acti-
vation of ULK1. Moreover, recent studies revealed novel pathways
through which AMPK activated autophagy. AMPK directly phosphory-
lates and activated ULK1, enabling the initiation of autophagy [11–13].
The association of AMPK with autophagy during cardiac ischemia was
further veriﬁed by the ﬁnding that autophagy in the initial phase of is-
chemia was accompanied by AMPK activation and was diminished by
dominant negative AMPK [14,15]. AMPK is an essentialmolecule for au-
tophagy initiation in cardiac ischemia. Joungmok Kim et al. found that
AMPK phosphorylation (Ser 317 and Ser 777) is required for ULK1 func-
tion in glucose starvation induced autophagy [16,17]. AMPK functions
as a nutrient sensor in mediating autophagy machinery in response to
energy crisis during cardiac ischemia.2.2. Hypoxia and HIF-1α also participated in autophagy initiation in cardiac
ischemia
Hypoxia-inducible factor 1 alpha (HIF-1α) is a key molecule regulat-
ing oxygen homeostasis. It could be activated by low oxygen or increased
oxidative stress during cardiac I/R conditions, working potentially as a
protective response. In vitro studies revealed that HIF-1αmediated mito-
chondrial autophagy as an adaptive metabolic response under hypoxia
conditions in mouse embryo ﬁbroblasts, but the correlation between
HIF-1α and autophagy in the diseasemodel of cardiac I/R has not been il-
lustrated [18]. Sinceprevious researches conﬁrmed thatHIF-1α activation
exerts cardio-protection during I/R, it will be interesting to ﬁgure out
whether the beneﬁcial effects of HIF-1α against cardiac I/R injury are
partly mediated by autophagy in cardiomyocytes.2.3. Beclin-1 mediated autophagy during cardiac reperfusion phase
Beclin1 (mammalian ortholog of yeast Atg6) plays an essential role
in mediating autophagy process, especially in the phase of reperfusion.
Since AMPK is no longer activated in reperfusion, it is not the major
mediator of autophagy in this phase. Enhanced autophagy during reper-
fusion is accompanied by upregulation of Beclin1 instead of AMPK, indi-
cating that Beclin-1 protein plays a vital role in autophagy in the phase
of reperfusion [14]. Overexpression of Beclin1 increased autophagic ac-
tivity during I/R in vitro [19]. Conversely, depletion of Beclin1 by siRNA
transfection or Beclin1 mutation mice attenuated autophagic activity
of cardiomyocytes during reperfusion [20].
Beclin1 is a key autophagic protein regulating both autophagosome
formation and processing. Collectively, the up-regulation of Beclin1 is
responsible for autophagy activation during reperfusion. However, the
question on how cardiac I/R injury activates Beclin1 remains to be elu-
cidated. One possible mechanism is its association with Bcl-2 protein.
In vitro study revealed that Beclin1 mediated autophagic response to
nutrient deprivation in cardiac cells is modulated by Bcl-2 protein
[21]. In addition, reactive oxygen species (ROS) may also be a strong in-
ducer of Beclin-1 in mediating autophagy during reperfusion [22]. In-
stead of energy crisis, increased ROS generation is a major promoter of
autophagy during reperfusion. Reperfusion phase causes increased oxi-
dative stress and is accompanied by Beclin1 overexpression. Antioxi-
dant MPG intervention signiﬁcantly suppressed Beclin1 up-regulation,
suggesting that ROS may play a key role in mediating Beclin1 up-
regulation [22]. Apart from regulating Beclin1 expression, ROS could ox-
idize and decrease Atg4 activity, contributing to LC3 lipidation and
autophagy initiation [23]. Furthermore, as Beclin1 is primarily located
in ER, whether ER stress induced by reperfusion conditions also partic-
ipates in Beclin1 up-regulation needs further exploration.
2.4. “Impaired” autophagic ﬂux in cardiac reperfusion phase
Autophagicﬂux is a dynamic cellular biological process, from the for-
mation of autophagosome, autophagosome–lysosome fusion to ﬁnal
degradation. It has been deemed that autophagy is further enhanced
during cardiac reperfusion phase by providing evidence for accumulat-
ed autophagosomes in cardiomyocytes. However, we could not exclude
the possibility that the increased formation of autophagosomes during
I/Rwas resulted from decreased autophagosome clearance. Interesting-
ly, X. Ma et al. recently proposed a novel view that autophagic ﬂux was
partly “impaired”, instead of “excessively activated” during the phase of
reperfusion. They found that autophagosome clearancewas dramatical-
ly decreased with reperfusion in cardiomyocytes, which is detrimental
to cardiomyocyte survival during reperfusion [24,25]. This is a novel dis-
covery that is contrary to our traditional view that autophagy is further
enhanced during reperfusion phase. This ﬁnding also gives rise to the
importance of detecting “intact autophagic ﬂux” to reveal the accurate
level of autophagy. Additionally, it is of necessity that researchers re-
evaluate the previously published results inwhichpure autophagosome
abundance was used to reﬂect the extent of autophagic activity.
3. Double-edged sword biological function of autophagy in
myocardial I/R injury
3.1. Autophagy mediated ATP generation alleviates energy crisis during
myocardial ischemia phase
Sufﬁcient ATP supply is an essential requirement for constitutively
contrasting cardiomyocytes. However, during the phase of ischemia,
ATP generation is decreased due to damaged mitochondrial function
and uncoupled phosphorylation. Decreased ATP level is an indirect
inducer of cardiomyocyte autophagy via AMPK activation. Low ATP
level is capable of activating the energy sensor AMPK, followed by
up-regulation of AMPK-mTORC1-ULK1 signaling and autophagy
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and amino acids are released, and subsequently recycled to generate
ATP through tricarboxylic acid cycle (TCA cycle), compensating for
the energy crisis in the condition of cardiac ischemia. It was con-
ﬁrmed that inhibition of autophagy with 3-MA decreased ATP gener-
ation and aggravated cardiac cell death in response to glucose
deprivation [14]. Cardiac autophagy serves as an energy-recovering
process during ischemic phase and is essential for cardiomyocyte
survival.
3.2. Mitophagy compensates for mitochondrial injury during cardiac I/R
During theprocess of cardiac I/R,mitochondrialﬁssion and fragmen-
tation are observed in cardiomyocytes [26,27]. Excessive dysfunctional
and damaged mitochondrial during I/R would cause inﬂammation re-
sponse and ROS over-production, resulting in myocardial cell death
[28]. Under this condition, autophagy is induced to remove the dysfunc-
tional mitochondrial, a process known as mitochondrial autophagy,
namely, mitophagy [29,30]. During the initial phase of ischemia, the ac-
tivation of autophagy functions primarily to maintain energy balance
through recovering ATP generation, whereas to switch to damaged or-
ganelle or protein clearance in the later phase of ischemia and reperfu-
sion. Undoubtedly, mitophagy is a protective form of autophagy during
I/R injury, preventing damaged mitochondrial from releasing cytotoxic
substances.
3.3. Autophagy contributes to proteostasis in I/R injury
There are basically two cellular processes responsible for protein
quality control through removal of aged or damaged proteins: autoph-
agy for long-lived andmacromolecular proteins, while ubiquitin protea-
some system (UPS) for short lived proteins [31]. Nevertheless, during
the process of I/R, UPS becomes dysfunctional (proteasome activity is
preferentially reduced, ubiquitinated proteins exceed the degradation ca-
pacity of proteasome), leading to increase in myocardial ubiquitinated
proteins and resultant protein aggregates [32]. Unlike UPS, autophagy
is activated after I/R, partly functioning to remove these cytotoxic
ubiquitinated proteins. Findings by Tannous, P. et al. demonstrated that
autophagic activity attenuated protein aggregation in myocardium [33].
Conversely, ubiquitinated proteins were increased in the myocardium of






Fig. 1.Mechanisms and functions of autophagcooperatively in protein quality controlling. Under the condition of cardi-
ac I/R, increased autophagic activity compensated for the impaired UPS
function, keeping proteolysis at an appropriate level.3.4. Detrimental effects of autophagy during reperfusion
Current researches demonstrate that autophagy can be a double-
edged sword in the pathological process of I/R injury [35]. Beneﬁcial
functions of autophagy during I/R could be attributed to ATP generation
and cellular homeostasis, but the underlying mechanisms of detrimen-
tal effects of autophagy in reperfusion are still unclear.
Uncontrolled excessive induction of autophagy in response to I/R in-
jury may contribute to autophagic cardiomyocyte death, evidenced by
the observation that autophagy suppression by 3-MA or Beclin1 siRNA
reduced cell death in cardiomyocyte I/R injury [20]. Autophagy is a
cellular process responsible for substrate degradation. If autophagy is
hyper-activated beyond a certain level to delete necessary proteins
or organelles, leading to cellular dysfunction, autophagic cell death
would occur.
Another reason for the detrimental effects of autophagy may be
attributed to the crosstalk between autophagy and apoptosis. As Bcl-2
inhibits Beclin1-dependent autophagy, Beclin1mediated autophagy ac-
tivation during reperfusion is associated with Bcl-2 down-regulation.
Notably, Bcl-2 protein also participates in the regulation of apoptosis.
Decreased expression of Bcl-2 may contribute to apoptotic cell death.
Another potential molecule that connects autophagy and apoptosis is
Bnip3, a pro-apoptotic member of Bcl-2 family. Studies demonstrated
that Bnip-3 is involved in autophagy upregulation in cardiac I/R [36].
However, it still remains to be clariﬁed, whether Bnip3 mediated au-
tophagy activation contributes to autophagic cardiomyocyte death, or
this autophagy opposes apoptotic cell death pathway.4. Potential therapeutic targets of autophagy for cardiac I/R injury
It has been a consensus that cardiac autophagy is involved in the
pathological progress of cardiac I/R. Therefore, autophagy has become
a potential therapeutic interest for researchers. Even though there are
no clinical trials targeting autophagy in cardiac I/R treatment, several
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Fig. 2.Dual regulative effects of Apelin in adipose derivedmesenchymal stem cell (ADMSC) autophagy in hypoxia–reoxygenation (H/R). Our recentﬁndings indicate that Apelin is capable
of dually regulating the activity of autophagy, improving cell viability of ADMSCs. In the phase of initial anoxia, Apelin up-regulated protective autophagy through the activation of AMPK-
mTOR-ULK1 pathway, while in the period of reoxygenation, Apelin suppressed excessive autophagic activity through Akt-Bcl2-Beclin1 signaling. The dual regulative effects of Apelin
through different signaling mechanisms keep ADMSC autophagy activity at a moderate level to be protective for cell survival.
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effects against I/R
As increasing lines of evidence have veriﬁed that AMPK activation
during the initial phase of cardiac ischemia contributes to protective au-
tophagy, pharmacologic drugs for AMPK activation are increasingly at-
tractive as therapeutic targets. In vitro evidence showed that AMPK
activation by acetylcholine elicited autophagy and induced tolerance
against H9c2 cell H/R injury [37]. D942, a cell-permeable compound
could also activate AMPK, induce autophagy and exert cardioprotective
effects against I/R [38]. A great number of clinical drugs have been
shown to activate AMPK, for instance, D942, metformin and stains
[39]. These pharmacological compounds may activate AMPK through
the regulation of AMP/ATP ratio indirectly. Additionally, Agnes S. Kim
et al. reported that a directing AMPK activation via small molecule
A-769662 signiﬁcantly alleviated cardiac I/R injury in vivo and they
demonstrated that pre-treatment of AMPK activation was sufﬁcient
to replicate the beneﬁcial function of ischemic preconditioning [40].
Even though AMPK mediated autophagy is protective in cardiac I/R,
some concern still remains. One point is that AMPK activation could
stimulate fatty acid metabolism while reduce glucose oxidation,
resulting to less efﬁcient myocardium metabolism. Moreover, using
drugs to activate AMPK systemically may possibly increase food intake
by hypothalamus stimuli. Further studies should be directed to under-
stand the feasibility of AMPK activation in cardiac I/R treatment.
4.2. Autophagy regulation through selective activation of mTOR system is
associated with enhanced cardiac cell survival after I/R
Mammalian target of rapamycin (mTOR) is a serine/threonine ki-
nase, associating with speciﬁc adaptor proteins to form 2 types of
multiprotein complexes, mTOR complex 1 (mTORC1) and mTOR com-
plex 2 (mTORC2) [41]. Wu, X. et al. reported that valsartan precondi-
tioning signiﬁcantly reduced cardiac infarction size through autophagyup-regulation via PI3K-Akt-mTORC1 pathway [42]. However, Toshinori
Aoyagi et al. recently reported that overexpression of cardiac mTORC1
protected the heart from I/R injury [43]. This seems to be a contradiction
to our conclusions as mTORC1 overexpression would suppress the pro-
survival process of autophagy in myocardium. In fact, the beneﬁcial ef-
fects of mTORC1 over-expression are mainly attributed to the suppres-
sion of inﬂammatory response during reperfusion, and the beneﬁts of
decreased inﬂammatory response exceed the functional loss of autoph-
agy. These ﬁnding also indicates the complexity of mTORC1 function in
a particular diseasemodal. A speciﬁcmoleculemay be associatedwith a
variety of cellular pathways and havemultiple functions. A comprehen-
sive study and evaluation of mTORC1 should be illuminated before clin-
ical usage for autophagy regulator in cardiac I/R patients.
Additionally, we recently uncovered some interesting ﬁndings in the
regulative function of Apelin on adipose derivedmesenchymal stem cell
(ADMSC) autophagy in the disease model of hypoxia–reoxygenation
(Fig. 1). Similar with cardiac I/R injury, ADMSC autophagy is activated
in the initial hypoxia phase and excessively enhanced in the period of
reoxygenation. Notably, Apelin is capable of dually regulating the activ-
ity of autophagy, improving cell viability of ADMSCs. In the phase of
initial anoxia, Apelin up-regulated protective autophagy through the ac-
tivation of AMPK-mTOR-ULK1 pathway, while in the period of reoxy-
genation, Apelin suppressed excessive autophagic activity through
Akt-Bcl2-Beclin1 signaling. The dual regulative effects of Apelin through
different signaling mechanisms keep ADMSC autophagy activity at a
moderate level to be protective for cell survival. Our in vitro results
bring some illumination to the therapies on cardiac I/R injury. It is inter-
esting to ﬁnd a pharmacological regulator to adjust cardiac autophagy
to a moderate extent, thus exerting protective effects during the period
of both ischemia and reperfusion.
Interestingly, researchers found that the activation of mTORC2 also
participated in the induction of autophagy, andwas associated with en-
hanced cardiac cell survival after I/R [44]. Recently, Völkers,M. et al. pro-
posed a novel approach for cardiac ischemia by selectively increasing
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moderate regulation of autophagy, via either PI3K-Akt-mTORC1 path-
way or mTORC1/mTORC2 balancing, may serve as a potential strategy
in cardiac I/R treatment (Fig. 2).
4.3. Other potential agents targeting autophagy for cardiac I/R injury
A series of preclinical studies have revealed the potential
cardioprotective beneﬁts of histone deacetylase (HDAC) inhibitors in
myocardial I/Rmodel. In a recent study byMinXie et al., they uncovered
that autophagic ﬂux in myocardium infarct border zone was required
for the cardio-protective activity of HDAC inhibitor, suberoylanilide
hydroxamic acid (SAHA) [46]. SAHA has been approved for cancer
treatment by the US Food andDrugAdministration. Their study demon-
strates that autophagy activation by SAHA pretreatment or SAHA treat-
ment during reperfusion is beneﬁcial for cardiac I/R. More importantly,
this study was performed with a preclinical trial in a large-animal of
rabbits, using several clinical trial methodologies such as randomiza-
tion, pre-established end points and strict blinding of personnel. As
SAHA serum concentrations in rabbits are achievable in human sub-
jects, SAHAwas shown as a potential agent for its control of cardiomyo-
cyte autophagy. However, safety is an important issue that should be
addressed. Before it will eventually be applied as a therapeutic strategy
in clinical I/R injury, pharmaceutic side effects of SAHA and its molecu-
larmechanisms of its associationwith cardiomyocyte autophagy should
be fully understood.
5. Summary
Currently, the consensus is emerging that autophagy activation dur-
ing cardiac I/R could either antagonize cardiac pathogenesis or contrib-
ute to further myocardium damage, but the underlying mechanism is
still unclear. The debate focuses on the detrimental effects of autophagy
in I/R. One hypothesis is that excessive autophagy aggravates tissue
damage during the period of reperfusion when the heart is load-
stressed, accompanied with over-deletion of key organelles or proteins
in cardiomyocytes. Besides, some researchers attributed the detrimen-
tal effects of autophagy to its association with apoptosis. Several drugs
targeting the key molecular of autophagy such as mTOR or Beclin-1
have been applied, for the purpose of alleviating I/R injury in myocardi-
umby regulating the process of autophagy. The key is to suppress exces-
sive autophagywithout eliminating basal autophagy, tuning autophagic
activity within moderate range for therapeutic beneﬁt in cardiac I/R. In
future studies, understanding the function and molecule machinery of
autophagy in cardiac I/R injury and exploring potential therapeutic tar-
gets of autophagy have signiﬁcant clinical implications.
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